Open AccessFibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease
Author(s) -
Orlando M. Gutiérrez,
James L. Januzzi,
Tamara Isakova,
Karen Laliberte,
Kelsey Smith,
Gina Collerone,
Ammar Sarwar,
Udo Hoffmann,
Erin Coglianese,
Robert H. Christenson,
Thomas J. Wang,
Christopher R. deFilippi,
Myles Wolf
Publication year - 2009
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.108.844506
Subject(s) - medicine , left ventricular hypertrophy , fibroblast growth factor 23 , cardiology , kidney disease , odds ratio , muscle hypertrophy , coronary artery disease , confidence interval , risk factor , calcification , body mass index , concentric hypertrophy , endocrinology , blood pressure , calcium , parathyroid hormone
Fibroblast growth factor 23 (FGF-23) is a phosphorus-regulating hormone. In chronic kidney disease (CKD), circulating FGF-23 levels are markedly elevated and independently associated with mortality. Left ventricular hypertrophy and coronary artery calcification are potent risk factors for mortality in CKD, and FGFs have been implicated in the pathogenesis of both myocardial hypertrophy and atherosclerosis. We conducted a cross-sectional study to test the hypothesis that elevated FGF-23 concentrations are associated with left ventricular hypertrophy and coronary artery calcification in patients with CKD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom